Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Net loss	$ (77,996)	$ (68,288)
Noncash adjustments reconciling net loss to cash flows from operating activities:
Loss on impairment of intangible assets	9,660	513
Share-based compensation expense	6,253	11,856
Noncash lease expense	2,730	1,582
Amortization of intangible assets	1,052	1,604
Depreciation and amortization	751	550
Loss on disposal of property and equipment	6	0
Accretion/amortization of investment securities, net	(510)	0
Change in fair value of redeemable noncontrolling interests	0	3,903
Changes in operating assets and liabilities:
Accounts receivable, net	863	(811)
Prepaid and other current assets and other long-term assets	(41)	(2,629)
Accounts payable	(1,829)	2,403
Accrued liabilities	(3,605)	10,502
Deferred revenue	(3,899)	(4,083)
Operating lease liabilities	(2,110)	(1,742)
Net cash used in operating activities	(68,675)	(44,640)
Cash flows from investing activities:
Purchases of marketable debt securities, available-for-sale	(84,852)	0
Sales of marketable debt securities, available-for-sale	2,188	0
Proceeds from Sale and Maturity of Marketable Securities	37,000	0
Purchases of property and equipment	(1,054)	(1,956)
Acquisition of intangible assets	0	(1,250)
Net cash used in investing activities	(46,718)	(3,206)
Cash flows from financing activities:
Proceeds from short-term bridge loan	166,000	0
Repayment of short-term bridge loan	(166,000)	0
Proceeds from directors and officers insurance premium financing agreement	1,831	0
Payments of directors and officers insurance premium financing agreement	(905)	0
Proceeds from issuance of ordinary shares, net of issuance costs	138	148,732
Payments to acquire the Ambrx Shanghai noncontrolling interests	0	(20,966)
Payments of costs for the issuance of Series B preferred shares	0	(339)
Payments of costs for the issuance of ordinary shares	(136)	0
Net cash provided by financing activities	928	127,427
Effect of exchange rate changes on cash, cash equivalents and restricted cash	0	47
Net (decrease) increase in cash, cash equivalents and restricted cash	(114,465)	79,628
Cash, cash equivalents and restricted cash, beginning of period	170,906	91,278
Cash, cash equivalents and restricted cash, end of period	56,441	170,906
Supplemental information:
Cash paid for interest	963	0
Cash paid for income taxes	319	1
Noncash investing and financing activities:
Property and equipment costs in accounts payable and accrued liabilities	491	727
ROU assets and lease liabilities obtain through reassessment of an existing lease	0	11,455
Conversion of convertible preferred shares into ordinary shares	0	253,031
Reclassification of redeemable noncontrolling interests from temporary equity to current liabilities	0	43,403
Accretion of redeemable noncontrolling interests to fair value	0	42,324
Deferred initial public offering costs in accounts payable and accrued liabilities	0	136
Reclassification of accumulated other comprehensive loss upon settlement of redeemable noncontrolling interests	$ 0	$ 85